TY - JOUR
T1 - B7-Negative Versus B7-Positive P815 Tumor
T2 - Differential Requirements for Priming of an Antitumor Immune Response in Lymph Nodes
AU - Yang, Guchen
AU - Mizuno, Mark T.
AU - Hellström, Karl Erik
AU - Chen, Lieping
PY - 1997/1/15
Y1 - 1997/1/15
N2 - Efficient T cell activation requires two synergistic but distinct signals derived from antigenic peptides presented by the MHC and from costimulatory molecules, particularly those belonging to the B7 family. Lack of B7-CD28 interaction may cause unresponsiveness of T cells to subsequent exposure to Ag. Nevertheless, immunization by some B7- tumors induces an antitumor immune response. We found that the immune response against two B7- tumors, the mouse P815 mastocytoma and the E7C3 melanoma, requires host-derived B7, since blockage of the B7-CD28 interaction facilitates tumor growth and eliminates an antitumor response. B7 costimulation is provided in the regional, tumor-draining lymph nodes for the induction of a primary CTL response against both B7+ tumor and B7- tumor. However, the induction of a CTL response to B7+ tumors and its clonal expansion may occur at tumor sites in addition to secondary lymphoid organs so as to generate more effective tumor immunity.
AB - Efficient T cell activation requires two synergistic but distinct signals derived from antigenic peptides presented by the MHC and from costimulatory molecules, particularly those belonging to the B7 family. Lack of B7-CD28 interaction may cause unresponsiveness of T cells to subsequent exposure to Ag. Nevertheless, immunization by some B7- tumors induces an antitumor immune response. We found that the immune response against two B7- tumors, the mouse P815 mastocytoma and the E7C3 melanoma, requires host-derived B7, since blockage of the B7-CD28 interaction facilitates tumor growth and eliminates an antitumor response. B7 costimulation is provided in the regional, tumor-draining lymph nodes for the induction of a primary CTL response against both B7+ tumor and B7- tumor. However, the induction of a CTL response to B7+ tumors and its clonal expansion may occur at tumor sites in addition to secondary lymphoid organs so as to generate more effective tumor immunity.
UR - http://www.scopus.com/inward/record.url?scp=0031567899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031567899&partnerID=8YFLogxK
M3 - Article
C2 - 8993003
AN - SCOPUS:0031567899
SN - 0022-1767
VL - 158
SP - 851
EP - 858
JO - Journal of Immunology
JF - Journal of Immunology
IS - 2
ER -